Calidi Biotherapeutics announced a $2 million strategic investment by Dr. Ronald Rigor into its new subsidiary, Nova Cell, to advance Calidi’s Adult Adipose Allogeneic stem cell innovative programs. Dr Rigor also invested an additional $1 million into Calidi to further its oncology pipeline of assets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
- Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
- Calidi announces issuance of U.S. patent on SuperNova tech platform
- Calidi appoints Mark Gilbert to Medical Advisory Board
- Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board